把钛植入自己手臂的人：邦美创始人米勒的执念 01 一个中年男人卷起袖子，把手臂伸到 X 光机下。片子上，一小段钛合金清晰地映在骨骼旁。医生们难以置信——那不是意外，而是他自己要求植入的。 "这是钛合金，它在我手臂里已经十年了。你们可以放心，它是安全的。" 这个男人，就是 Dane A. Miller（戴恩·A·米勒，约1946–2015）， Biomet（邦美） 的联合创始人兼长期 CEO。三十年间，他把公司从印第安纳州一间租 来的谷仓，带到全球骨科器械的巅峰。而他自己，凭借一段金属，成为了业内津津乐道的传奇。 米勒在 1978 年成为 CEO，并一直担任到 2006 年。三十年间，他把邦美带到年营收超过 20 亿美元、雇员 4000 多人的规模。代表性产品如 AGC 膝关节 系统，成为行业标准。 更重要的是，他建立了邦美独特的文化："can-do family"。在这里，工程师和员工被鼓励承担风险、快速试错；医生的意见被视为产品进化的核心。这种 文化，既是创业气质，也带有浓厚的中西部实干精神。 "钛合金实验"：用身体换来信任 04 从平凡少年到材料科学博士 02 米勒出生于俄亥俄州斯普林菲尔德，成长环境并不 ...

医疗设备行业正在经历一场"静悄悄的转型"。 过去十年，厂商与医院的关系多以设备采购为中心——一次交易，完成交付。而如今，面对持续上升的运营成本与人力压力，医院更需要的是"可持续协作伙伴"， 而非"单一供应商"。 GE HealthCare（纳斯达克代码：GEHC）正在系统地重构这种关系。 在北美市场，公司以"Care Alliance"（关护联盟）为名，建立起一类跨越数年、覆盖多业务板块的企业级合作模式。 它的本质，是将设备更新、AI数字服务、流程 再造、教育培训与融资支持纳入统一框架，共同承担风险与收益。 近期的几个案例清晰展示了这一趋势： 这些数字背后，是一家医疗科技巨头在"后装机时代"的自我重构：从销售产品，到共建体系。 # 三重挑战：医院为何需要"企业级合作" GE HealthCare美国与加拿大区总裁 Catherine Estrampes 在 AdvaMed's MedTech Conference 上解释道："我们所有合作的起点，都是理解客户的挑战与愿 景。" 与加州大学圣迭戈分校医学中心（UC San Diego Health）达成14年长期合作协议； 与Sutter Health签订7年期 ...

文章来源： 医健未来领袖 转载要求：可以直接转载 医疗器械/IVD的大部分经销商老板，在用旧地图寻找新大陆。 但现实却是： 大批设备集采、试剂"量价齐跌"，合规日趋严苛，同质化竞争持续不断……那个依靠信息不对称、简单"搬运"即可高歌猛进的时代正在落幕。 厂家指标+压货，医院回款+客情，都在消耗经销商现金流。 想转型，怕投入打水漂；想组织变革，怕反而影响团队。 核心在于企业需要完成从"被动应对"到"主动规划"，从"单纯流通"到"团队升维"的 "破局与重构" 。 别在无尽的忙碌中，耗尽最后的利润。 当老板，到底是在经营一门生意，还是在经营一套可持续、能复制、抗风险的"增长系统"？ 本次峰会核心聚焦"增长新引擎"： 定目标： 不再空谈理想，学习如何科学分解厂家指标，制定可执行、可追踪的团队路径图。 追过程： 破解团队管理黑洞，掌握业务员过程管控与效率提升的工具方法，让管理出效益。 拿结果： 在集采新常态下，找到利润增长点。从《科学选品》避开陷阱找到蓝海，到《科室定位》实现精准破局，再到 《经销商团队销售》 《税务风险防 控》与《涉法案件解析》保障经营安全，我们全方位护航结果落地。 建团队： 激发团队潜能，锻造能够适 ...

2025年10月29日晚， 联影医疗 公布了其2025年第三季度及前三季度业绩： 第三季度公司实现营业收入约 28.43 亿元，同比增长约 75.41% ；前三季度累计营 收约 88.59 亿元，同比增长约 27.39%。此外，前三季度归属于上市公司股东净利润约 11.20 亿元，同比增长约 66.91%。 这组数据标志着联影在高端影像设备领域的增长态势进一步显现，公司正从"国内追赶"迈向"全球标杆"的角色。 # 核心数据亮点 | 项目 | 本报告期 | 本报告期比 上年同期増 | | 年初至报告 期末比上年 | | --- | --- | --- | --- | --- | | | | 减变动幅度 | 年初至报告期末 | 同期增减变 | | | | (%) | | 动幅度(%) | | 营业收入 | 2.843.014.990.57 | 75. 41 | 8, 858, 916, 392. 73 | 27. 39 | | 利润总额 | 105,580,595.53 | 不适用 | 1, 178, 552, 726. 27 | 65. 56 | | 归属于上市公司股东 | 122, 216, 265. 88 ...

2025年10月29日，NMPA公布了创新医疗器械特别审查申请审查结果公示（2025年第10号），有7款产品进入创新通道。 1 . 自膨式颅内药物 洗脱 支架 系统 利兰生物科技（苏州）有限公司总部位于苏州，是一家专注于神经血管介入医疗器械研发、生产和销售的高新技术企业。公司致力于颅内支架、药物洗脱系统等创 新产品的开发，依托先进的生物材料技术和临床合作平台，旨在为脑血管疾病患者提供微创、安全的治疗解决方案，已获得多项国家专利，并与多家三甲医院开展 临床验证，推动神经介入领域的国产化创新。 2 . 植入式无线脑机 接口 系统 申请人 ：上海阶梯医疗科技有限公司 上海阶梯医疗科技有限公司成立于2021年8月，总部位于上海，是一家 专注于植入式脑机接口领域的创新型科技企业 。公司致力于微创植入式脑机接口技术的研发 与应用，产品可应用于运动控制（如瘫痪、精细肢体控制、失语）、神经疾病病灶监测及调控（如帕金森症、抑郁症）、感知觉修复（如失明、失聪）等多个领 域。 公司已成功研制中国首款符合医疗器械标准的高通量植入式脑机接口系统，入选工信部2023年未来产业创新任务"揭榜挂帅"项目，并获得上海市2024年度"科技创新 ...

2025年10月30日， 国医通（北京）科技发展有限公司 宣布完成 近亿元人民币D轮融资 ，由浙生协同生命健康基金独家领投。本轮资金将主要用于核心在研产品推 进、市场化落地与新产线建设。对于一家成立八年的血液净化企业而言，这不仅是阶段性成果，也是整个赛道进入"体系建设周期"的缩影。 血透是慢病治疗体系里周期最久、连续性最强、风险容忍度最低的细分领域之一。市场增长明确，但行业壁垒也更高。过去几年，从大型三甲医院到县域医疗再到 独立透析中心，透析需求不断渗透；与此同时，企业竞争逻辑从单品差异走向综合能力建设。国医通此次融资落地，恰逢行业"能力竞争"阶段加速成型。 # 需求扩容与结 构迁 移：血液净 化赛道进入关键 窗口 目前，公司已为上千家医疗机构提供服务，其中基层机构占比持续提升。这一结构变化说明，企业的服务能力不仅覆盖高水平临床场景，也能够嵌入资源相对有限 的地区，实现标准化建设与运营支撑。这种下沉能力，是透析产业扩张期的重要能力门槛。 根据行业统计，我国血液透析患者已超过百万，并呈持续增长趋势。老龄化、糖尿病发病率上行、CKD早筛逐步推进，使得透析需求具备稳定增长基础。与此同 时，分级诊疗政策持续推动服务重 ...

Core Viewpoint - The approval of three innovative products by Hangzhou Jialiang Medical Technology Co., Ltd. marks a significant breakthrough in domestic MRI-guided neurosurgical minimally invasive treatment equipment, enhancing treatment options for drug-resistant epilepsy patients [2][5][18]. Product Approval Information - On October 29, 2025, the National Medical Products Administration approved three innovative products: "MRI Monitoring Semiconductor Laser Treatment Device," "Disposable Laser Fiber Kit," and "Stereotactic Surgery Planning Software" [2][3]. - The total number of innovative medical devices approved in China has reached 377 [2]. Product Composition and Functionality - The MRI Monitoring Semiconductor Laser Treatment Device consists of a main unit and accessories, while the Disposable Laser Fiber Kit includes a medical fiber catheter component and a cooling water pipe. The Stereotactic Surgery Planning Software comprises an installation USB drive and a key [4][13]. - These products are designed for laser ablation treatment of focal lesions in drug-resistant epilepsy patients, utilizing MRI imaging for precise monitoring during surgery, thereby minimizing damage to normal brain tissue and preserving cognitive function [4][11]. Company Overview - Hangzhou Jialiang Medical Technology Co., Ltd. was established in 2020 and focuses on the industrialization of cutting-edge technologies in brain science and neurosurgery. The company has developed three major technology platforms: brain-machine control, medical lasers, and brain-machine chips [8]. - The company has established dual headquarters in China and Singapore, with a GMP production base and a professional R&D center, promoting independent innovation and global application of high-end neurosurgical systems [8]. Core Product Layout - The LaserRO™ MRI-guided laser ablation minimally invasive surgical system is a key component of the company's offerings, combining real-time MRI monitoring with laser fiber technology for targeted ablation of diseased tissue [9][11]. - The system is designed to provide a new treatment option for drug-resistant epilepsy patients, significantly reducing damage to normal brain tissue and enhancing cognitive function preservation [11][18]. Conclusion - The approval of these three innovative products opens a new technological dimension for domestic neurosurgical equipment, integrating real-time MRI monitoring, precise energy delivery, and surgical path planning, thus enhancing the treatment of complex brain diseases [18]. - This innovation not only fills technological gaps in individual products but also establishes a clinical system that integrates imaging, energy, and algorithms, positioning brain science as a new growth driver for domestic high-end medical device innovation [18].

Core Viewpoint - Mindray Medical's third-quarter performance indicates a revenue recovery after adjustments, but profitability remains under pressure, signaling a critical transition period for the company as it focuses on medical device manufacturing and internationalization [2][3]. Group 1: Financial Performance - In Q3, Mindray achieved revenue of approximately 9.09 billion yuan, a year-on-year increase of about 1.53%, while net profit was around 2.50 billion yuan, down approximately 18.69% [3]. - For the first three quarters, cumulative revenue was about 25.83 billion yuan, a year-on-year decline of approximately 12.38%, and net profit was about 7.57 billion yuan, down approximately 28.83% [3]. - The company reported a decrease in basic earnings per share to 2.0641 yuan, down 18.62% year-on-year [3]. Group 2: Product and Business Structure - Mindray's business is structured around three main lines: Life Information and Support, Medical Imaging, and In Vitro Diagnostics (IVD) [4]. - The Life Information and Support segment generated approximately 2.95 billion yuan in revenue, with a year-on-year growth of about 2.60% [5]. - The Medical Imaging segment's revenue was approximately 1.69 billion yuan, showing little change year-on-year, while the IVD segment reported revenue of about 3.63 billion yuan, a slight decline of approximately 2.81% [5]. Group 3: International Market Acceleration - Mindray's international business grew by approximately 11.93% year-on-year in Q3, with notable growth in Europe, Latin America, and some Asian and African markets [7]. - The company is transitioning from product exports to service coverage and from single equipment sales to comprehensive solutions, enhancing its global competitiveness [7]. Group 4: Domestic Market Challenges and Adjustments - Despite the acceleration in international business, the domestic market remains crucial for Mindray, facing growth challenges due to policy and procurement factors [8]. - The company is implementing key changes to adapt to the complex domestic environment, aiming to shift from "quantity growth" to "quality improvement" [8]. Group 5: Strategic Focus - Mindray's current strategy emphasizes product upgrades and ecosystem building, focusing on high-end product lines and integrating data, algorithms, and services into its offerings [9][10]. - The company aims to enhance its service capabilities and customer loyalty by transitioning from equipment sales to comprehensive healthcare solutions [12]. Group 6: Summary - Mindray's third-quarter results reflect ongoing challenges, but its product structure optimization and international market acceleration present positive signals [13]. - The company's future growth will depend on the successful implementation of its strategies, including product deployment, international market scaling, and ecosystem development [13][15].

Core Viewpoint - The article discusses the upcoming Fourth China Plastic Surgery and Regenerative Medicine Development Conference and the 14th Beijing International Aesthetic Surgery Conference, scheduled for October 31 to November 2, 2025, in Beijing, aimed at promoting the development of plastic surgery and enhancing collaboration among related disciplines [2]. Event Overview - The conference will feature a main forum, an innovation transformation competition final, and nine sub-forums, with a total expected attendance of around 500 participants [5][6]. - The event is organized by the Chinese Academy of Medical Sciences Plastic Surgery Hospital and the Beijing Eight Great Places Aesthetic Medical Technology Group [4]. Main Forum Agenda - The main forum will include a welcome address, opening speeches, and a series of thematic presentations covering topics such as innovative medical technology, marketing integration in medical devices, and advancements in skin chip technology [5][6][7]. - Notable speakers include leaders from various medical and technological institutions, discussing the intersection of innovation and medical aesthetics [6]. Innovation Transformation Competition - The competition will focus on showcasing innovative achievements in plastic surgery and aesthetic medicine, providing a platform for project and capital matchmaking [7]. - Projects will cover diverse areas including materials, devices, and digital applications, highlighting the journey from research to clinical application [7][8]. Investment and Financing Sub-Forum - A dedicated sub-forum on investment and financing in the aesthetic medicine sector will take place on November 2, featuring discussions on industry trends and investment opportunities [9][10]. - Key topics will include the current state of the aesthetic medicine industry, insights into the light medical beauty sector, and strategies for integrating upstream and downstream resources [10]. Additional Forums - Various sub-forums will address topics such as medical device safety, digital transformation in aesthetic medicine, and regenerative medicine applications, with specific sessions dedicated to emerging technologies and investment strategies [22][24][33].

为推动我国整形外科健康、蓬勃发展，增进整形外科与相关学科交流与合作， 中国医 学科学院整形外科医院 定于 2025年10月31日至11月2日 在 北京 举办第四届中国整 形外科与再生医学发展大会暨第十四届北京国际整形美容外科会议。同期举办 第三届 八大处整形美容产业论坛， 论坛由 北京八大处整形医疗科技集团有限公司、 北京医疗 整形美容业协会 主办。 大会设置主论坛、创新转化大赛决赛、及 9个分论坛 ，报名链接均见本文。 参会免费，现场有企业产品 展览， 欢迎报名！ 上一届论坛回顾： 概念验证驱动创新，医工交叉赋能医美：第二届八大处整形美容产 业论坛圆满召开 第三届中国八大处整形美容产业论坛 时间： 2025年10月31日 – 11月2日 地点： 北京市银保国际会议中心 主办单位： 北京八大处整形医疗科技集团有限公司、 北京医疗整形美容业协会 一、主论坛议程 会议时间： 2025年10月31日（星期五） 上午 会议规模： 约 500人 会议地点： 北京银保国际会议中心三层大会议厅 会议议程： 【开幕式】 9:00-9:05 致欢迎辞 | 中国医学科学院整形外科医院 | 副院长 | | --- | --- | ...